Format

Send to

Choose Destination
Cancer Lett. 2010 Aug 1;294(1):118-24. doi: 10.1016/j.canlet.2010.01.029. Epub 2010 Feb 11.

Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration.

Author information

1
Department of Technology and Product Development, CK Life Sciences Int'l., (Holdings) Inc., 2 Dai Fu Street, Tai Po Industrial Estate, Hong Kong SAR, China. tak.chan@ck-lifesciences.com

Abstract

Cucurbitacin B is an anti-cancer drug candidate and its efficacy has been demonstrated in hepatocellular carcinoma (HCC). To explore its mechanism against HCC, BEL-7402 cells were treated with cucurbitacin B in vitro. Treatment with cucurbitacin B induced S phase arrest and apoptosis. The growth inhibition effect was associated with cyclin D1 and cdc-2 down regulations. Western blotting analysis of cell signaling molecules indicated that cucurbitacin B inhibited c-Raf activation without affecting STAT3 phosphorylation. Moreover, in vivo study demonstrated that cucurbitacin B is effective against BEL-7402 xenograft when administrated orally.

PMID:
20153103
DOI:
10.1016/j.canlet.2010.01.029
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center